Subtype
Colon Neoplasm
CI-CAN-00004992Explore in graph →
Non-malignant271 active trials5 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004992Explore in graph →
Clinical trials
1,559 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06997497 | A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) | recruiting | Phase 3 | 477 | Merck Sharp & Dohme LLCINDUSTRY | 29 | Sep 28, 2026 | clinicaltrials |
| NCT05482516 | Evaluating Novel Therapies in ctDNA Positive GI Cancers(MRD-GI) | recruiting | Phase 3 | 20 | Georgetown UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03803553 | Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer | active not recruiting | Phase 3 | 400 | Massachusetts General HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05174169 | Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease(CIRCULATE-US) | recruiting | Phase 2 / Phase 3 | 1,912 | NRG OncologyOTHER | 3 | Sep 2, 2026 | clinicaltrials |
| NCT00217737 | Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer | completed | Phase 3 | 2,431 | National Cancer Institute (NCI)NIH | 5 | Aug 25, 2026 | clinicaltrials |
| NCT07669519 | Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line Chemotherapy(NuvastaticTM) | recruiting | Phase 3 | 180 | Natureceuticals Sdn BhdINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT01918527 | Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer | completed | Phase 3 | 250 | Vejle HospitalOTHER | 3 | Aug 21, 2026 | clinicaltrials |
| NCT06119867 | CompariSon Between the EuroPeAn and Japanese pathologiCal InvEstigation for Colon Cancer (SPACE)(SPACE) | recruiting | Phase 3 | 430 | Russian Society of Colorectal SurgeonsOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05534087 | Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)(CLAUDIA) | recruiting | Phase 3 | 236 | Seoul National University HospitalOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT02912559 | Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair | active not recruiting | Phase 3 | 712 | National Cancer Institute (NCI)NIH | 3 | Aug 4, 2026 | clinicaltrials |
| NCT05710406 | Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer | active not recruiting | Phase 2 / Phase 3 | 1 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07669454 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy.(NuvastaticTM) | recruiting | Phase 3 | 250 | Natureceuticals Sdn BhdINDUSTRY | 1 | Jun 25, 2026 | clinicaltrials |
| NCT00079274 | Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer | completed | Phase 3 | 3,397 | National Cancer Institute (NCI)NIH | 3 | Jun 23, 2026 | clinicaltrials |
| NCT06446557 | De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer(DIAMOND) | not yet recruiting | Phase 3 | 408 | University Hospital, RouenOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT00002968 | Edrecolomab in Treating Patients With Stage II Colon Cancer | completed | Phase 3 | 2,100 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02572141 | FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL)(OPTICAL) | active not recruiting | Phase 3 | 738 | Sun Yat-sen UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07412613 | Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer | recruiting | Phase 3 | 386 | AkesoINDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05179889 | Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer | recruiting | Phase 2 / Phase 3 | 308 | Chungnam National University HospitalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT01460589 | Early Commencement of Adjuvant Chemotherapy for Colon Cancer(ECTX) | active not recruiting | Phase 3 | 303 | Kyungpook National University HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03426904 | Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer | active not recruiting | Phase 3 | 708 | Kyungpook National University HospitalOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06107920 | Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy(COnCERTO) | recruiting | Phase 3 | 232 | University Hospital, RouenOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT02448173 | A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer | not yet recruiting | Phase 3 | 550 | Vaccinogen IncINDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT05177484 | Perioperative Iron for Colorectal Cancer (PICoC Study)(PICoC) | completed | Phase 3 | 40 | The Royal Wolverhampton Hospitals NHS TrustOTHER_GOV | 1 | Jan 30, 2026 | clinicaltrials |
| NCT05855200 | Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer | recruiting | Phase 3 | 892 | GlaxoSmithKlineINDUSTRY | 28 | Jan 23, 2026 | clinicaltrials |
| NCT06686576 | A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer | recruiting | Phase 3 | 363 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07272772 | Colon Cancer Diagnosis With FAPI-PET Imaging | recruiting | Phase 2 / Phase 3 | 100 | Turku University HospitalOTHER_GOV | 1 | Dec 9, 2025 | clinicaltrials |
| NCT06940947 | Endoscopic Therapy Or Surgery for Early Colon Cancer(ETHOS) | recruiting | Phase 3 | 434 | Norwegian Department of Health and Social AffairsOTHER_GOV | 1 | Nov 20, 2025 | clinicaltrials |
| NCT02967289 | IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting(IROCAS) | completed | Phase 3 | 792 | UNICANCEROTHER | 2 | Nov 17, 2025 | clinicaltrials |
| NCT01727388 | Informativeness to Digital Rectal Examination(RIFIONA) | completed | Phase 3 | 320 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04534075 | Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial(FIDURA) | completed | Phase 3 | 354 | Sahlgrenska University HospitalOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT06490536 | The Sagittarius Trial | recruiting | Phase 3 | 700 | IFOM ETS - The AIRC Institute of Molecular OncologyOTHER | 3 | Aug 29, 2025 | clinicaltrials |
| NCT07132008 | Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer | not yet recruiting | Phase 3 | 94 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT06208371 | Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM | recruiting | Phase 3 | 117 | Sun Yat-sen UniversityOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT02467582 | Adjuvant Aspirin Treatment for Colon Cancer Patients | terminated | Phase 3 | 1,040 | Swiss Cancer InstituteOTHER | 4 | May 16, 2025 | clinicaltrials |
| NCT04068103 | Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery | active not recruiting | Phase 2 / Phase 3 | 635 | NRG OncologyOTHER | 3 | May 7, 2025 | clinicaltrials |
| NCT03428477 | EPA for Metastasis Trial 2(EMT2) | active not recruiting | Phase 3 | 418 | Mark A Hull, PhD FRCPOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06910514 | Efficacy and Safety of a Solution for Endoscopic Mucosal Resection of Colonic Lesions | completed | Phase 3 | 52 | Nakafarma S.L.INDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT04322539 | A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer(FRESCO-2) | completed | Phase 3 | 691 | Hutchison Medipharma LimitedINDUSTRY | 14 | Apr 4, 2025 | clinicaltrials |
| NCT06293625 | Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced but Resecable Colon Cancer in the Elderly of 70 Years Old or More(FOxTROT2France) | recruiting | Phase 3 | 150 | Centre Hospitalier Universitaire DijonOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06899477 | Pre-Operative Treatment in REseCTable COlon CanceR | not yet recruiting | Phase 3 | 714 | Dominik Paul ModestOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT05709249 | Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer | recruiting | Phase 3 | 730 | Jiangsu Famous Medical Technology Co., Ltd.INDUSTRY | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06709144 | Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer(BLARCC) | active not recruiting | Phase 3 | 896 | Haixing Ju, MDOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06609551 | ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study(ZJCH-CRCC-1) | recruiting | Phase 3 | 312 | Zhejiang Cancer HospitalOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT04488159 | Immunoscore As Decision Guidance for Adjuvant Chemotherapy in Colon Cancer(iMAGINE) | withdrawn | Phase 3 | 0 | Johannes Laengle, MD, PhDOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT02355379 | Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over(ADAGE) | unknown | Phase 3 | 774 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT05021263 | Does IV Magnesium Improve Quality of Recovery With ERAS Protocols in Laparoscopic Colorectal Surgery? | completed | Phase 3 | 90 | Thomas Jefferson UniversityOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT03464305 | ASPIRIN Trial Belgium(ASPIRIN) | active not recruiting | Phase 3 | 148 | University Hospital, AntwerpOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT02301286 | A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients(ASPIRIN) | active not recruiting | Phase 3 | 770 | Leiden UniversityOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT05726097 | Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure | completed | Phase 3 | 147 | Region SkaneOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT02519140 | Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal Resections | withdrawn | Phase 3 | 0 | Antonios LikourezosOTHER | 1 | Dec 4, 2023 | clinicaltrials |
Data updated yesterdaySource updated Sep 28, 2026source: clinicaltrials